Targeting the type III secretion system to treat bacterial infections

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 2, 2014, Pages 137-152

  Marshall, Natalie C ^a,b   Brett Finlay, B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibiotic resistance; Antivirulence agents; Gram negative infections; Type III secretion system

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; PROTEIN INHIBITOR; TYPE III SECRETION SYSTEM INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBODY ENGINEERING; BACTERIAL INFECTION; BACTERIAL VIRULENCE; DRUG TARGETING; GASTROENTERITIS; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PLAGUE; PNEUMONIA; REVIEW; TYPE III SECRETION SYSTEM; TYPHOID FEVER;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; HUMANS; VIRULENCE;

EID: 84892606269     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.855199     Document Type: Review

References (108)

1. Clatworthy A, Pierson E, Hung D. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3:541-8
2. Watanabe T. Infective heredity of multiple drug resistance in bacteria. Bacteriol Rev 1963;27:87-115
3. Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol 2011;14:564-9
4. Lautenbach E, Polk R. Resistant gram-negative bacilli: a neglected healthcare crisis? Am J Health Syst Pharm 2007;64:S3-21.quiz S22
5. Coates A, Halls G. Antibiotics in Phase II and III clinical trials. Handb Exp Pharmacol 2012;211:167-83
6. Keyser P, Elofsson M, Rosell S, Wolf-Watz H. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Intern Med 2008;264:17-29
7. Chang J, Antonopoulos D, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8
8. Sekirov I, Russell S, Antunes L, Finlay B. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904
9. Von Behring E, Kitasato S. On the acquisition of immunity against diptheria and tetanus in animals. Dtsch Med Wochensch 1890;16:1145-8
10. Büttner D. Protein export according to schedule: architecture, assembly, and regulation of type III secretion systems from plant-and animal-pathogenic bacteria. Microbiol Mol Biol Rev 2012;76:262-310
11. Cornelis G. The type III secretion injectisome. Nat Rev Microbiol 2006;4:811-25
12. Zhou D, Galán J. Salmonella entry into host cells: the work in concert of type III secreted effector proteins. Microbes Infect Inst Pasteur 2001;3:1293-8
13. Collier-Hyams L, Zeng H, Sun J, et al. Cutting edge: salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J Immunol Baltim Md 1950;169:2846-50
14. Holmes A, Mühlen S, Roe AJ, Dean P. The EspF effector, a bacterial pathogen's Swiss army knife. Infect Immun 2010;78:4445-53
15. Kim D, Lenzen G, Page A-L, et al. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA 2005;102:14046-51
16. Swietnicki W, Carmany D, Retford M, et al. Identification of small-molecule inhibitors of Yersinia pestis type III secretion system YscN ATPase. PLoS ONE 2011;6:e19716
17. Gauthier A, Robertson M, Lowden M, et al. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 2005;49:4101-9
18. Perry R, Fetherston J. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997;10:35-66
19. Galindo C, Rosenzweig J, Kirtley M, Chopra A. Pathogenesis of Y. enterocolitica and Y. pseudotuberculosis in human Yersiniosis. J Pathog 2011;2011:182051
20. Majowicz S, Musto J, Scallan E, et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis Off Publ Infect Dis Soc Am 2010;50:882-9
21. Bhutta Z, Threlfall J. Addressing the global disease burden of typhoid fever. JAMA J Am Med Assoc 2009;302:898-9
22. Croxen M, Finlay B. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010;8:26-38
23. Smith K, Wilker P, Reiter P, et al. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 2012;31:37-41
24. Peng J, Yang J, Jin Q. Research progress in Shigella in the postgenomic era. Sci China Life Sci 2010;53:1284-90
25. Grier M, Garrity-Ryan L, Bartlett V, et al. N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: in vitro anti-virulence activity and metabolic stability. Bioorg Med Chem Lett 2010;20:3380-3
26. Cornelis G. The type III secretion injectisome, a complex nanomachine for intracellular "toxin" delivery. Biol Chem 2010;391:745-51
27. Sekiya K, Ohishi M, Ogino T, et al. Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure. Proc Natl Acad Sci USA 2001;98:11638-43
28. Izoré T, Job V, Dessen A. Biogenesis, regulation, and targeting of the type III secretion system. Struct Lond Engl 1993;19:603-12
29. Kubori T, Sukhan A, Aizawa S, Galán J. Molecular characterization and assembly of the needle complex of the Salmonella Typhimurium type III protein secretion system. Proc Natl Acad Sci USA 2000;97:10225-30
30. Pettersson J, Nordfelth R, Dubinina E, et al. Modulation of virulence factor expression by pathogen target cell contact. Science 1996;273:1231-3
31. Sorg I, Wagner S, Amstutz M, et al. YscU recognizes translocators as export substrates of the Yersinia injectisome. EMBO J 2007;26:3015-24
32. Deng W, Li Y, Hardwidge P, et al. Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens. Infect Immun 2005;73:2135-46
33. Barta M, Guragain M, Adam P, et al. Identification of the bile salt binding site on IpaD from Shigella flexneri and the influence of ligand binding on IpaD structure. Proteins 2012;80:935-45
34. Akeda Y, Galán J. Chaperone release and unfolding of substrates in type III secretion. Nature 2005;437:911-15
35. Schlumberger M, Müller AJ, Ehrbar K, et al. Real-time imaging of type III secretion: salmonella SipA injection into host cells. Proc Natl Acad Sci USA 2005;102:12548-53
36. Andersson K, Carballeira N, Magnusson K, et al. YopH of Yersinia pseudotuberculosis interrupts early phosphotyrosine signalling associated with phagocytosis. Mol Microbiol 1996;20:1057-69
37. Lee P-C, Stopford C, Svenson A, Rietsch A. Control of effector export by the Pseudomonas aeruginosa type III secretion proteins PcrG and PcrV. Mol Microbiol 2010;75:924-41
38. Veenendaal A, Hodgkinson J, Schwarzer L, et al. The type III secretion system needle tip complex mediates host cell sensing and translocon insertion. Mol Microbiol 2007;63:1719-30
39. Chen Y, Anderson D. Expression hierarchy in the Yersinia type III secretion system established through YopD recognition of RNA. Mol Microbiol 2011;80:966-80
40. Anderson D, Ramamurthi K, Tam C, Schneewind O. YopD and LcrH regulate expression of Yersinia enterocolitica YopQ by a posttranscriptional mechanism and bind to yopQ RNA. J Bacteriol 2002;184:1287-95
41. Cambronne E, Schneewind O. Yersinia enterocolitica type III secretion: yscM1 and yscM2 regulate yop gene expression by a posttranscriptional mechanism that targets the 5' untranslated region of yop mRNA. J Bacteriol 2002;184:5880-93
42. Kauppi A, Nordfelth R, Uvell H, et al. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 2003;10:241-9
43. Pan N, Brady M, Leong J, Goguen J. Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 2009;53:385-92
44. Felise H, Nguyen H, Pfuetzner R, et al. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 2008;4:325-36
45. Linington R, Robertson M, Gauthier A, et al. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org Lett 2002;4:4089-92
46. Michiels T, Wattiau P, Brasseur R, et al. Secretion of Yop proteins by Yersiniae. Infect Immun 1990;58:2840-9
47. Li X, Kang F, Macielag M. Triazine compounds as inhibitors of bacterial type III protein secretion systems. WO 2005111017 A1; 2005
48. Yount J, Tsou L, Dossa P, et al. Visible fluorescence detection of type III protein secretion from bacterial pathogens. J Am Chem Soc 2010;132:8244-5
49. Van Engelenburg S, Palmer A. Imaging type-III secretion reveals dynamics and spatial segregation of Salmonella effectors. Nat Methods 2010;7:325-30
50. Van Engelenburg S, Palmer A. Quantification of real-time Salmonella effector type III secretion kinetics reveals differential secretion rates for SopE2 and SptP. Chem Biol 2008;15:619-28
51. Enninga J, Mounier J, Sansonetti P, Tran Van Nhieu G. Secretion of type III effectors into host cells in real time. Nat Methods 2005;2:959-65
52. Tsou L, Dossa P, Hang H. Small molecules aimed at type III secretion systems to inhibit bacterial virulence. Med Chem Comm 2013;4:68-79
53. Li J, Lv C, Sun W, et al. Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2013;57:2191-8
54. Kimura K, Iwatsuki M, Nagai T, et al. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot (Tokyo) 2011;64:197-203
55. Vikram A, Jayaprakasha G, Jesudhasan P, et al. Suppression of bacterial cell-cell signalling, biofilm formation and type III secretion system by citrus flavonoids. J Appl Microbiol 2010;109:515-27
56. Willing B, Antunes L, Keeney K, et al. Harvesting the biological potential of the human gut microbiome. Bio Essays News Rev Mol Cell Dev Biol 2011;33:414-18
57. Gallegos M, Schleif R, Bairoch A, et al. Arac/XylS family of transcriptional regulators. Microbiol Mol Biol Rev MMBR 1997;61:393-410
58. Garrity-Ryan L, Kim O, Balada-Llasat J-M, et al. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 2010;78:4683-90
59. Ozawa I, Takeuchi I, Yamamoto K, et al. Synthesis and antimicrobial activity of salicylanilide derivatives. II. Chem Pharm Bull (Tokyo) 1984;32:305-12
60. Bowser T, Bartlett V, Grier M, et al. Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. Bioorg Med Chem Lett 2007;17:5652-5
61. Kim O, Garrity-Ryan L, Bartlett V, et al. N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 2009;52:5626-34
62. Dahlgren M, Kauppi A, Olsson I-M, et al. Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides-potent inhibitors of type III secretion in Yersinia. J Med Chem 2007;50:6177-88
63. Chène P. AT Pases as drug targets: learning from their structure. Nat Rev Drug Discov 2002;1:665-73
64. Hilleringmann M, Pansegrau W, Doyle M, et al. Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiol Read Engl 2006;152:2919-30
65. Young G, Schmiel D, Miller V. A new pathway for the secretion of virulence factors by bacteria: the flagellar export apparatus functions as a protein-secretion system. Proc Natl Acad Sci USA 1999;96:6456-61
66. Vijay-Kumar M, Aitken J, Carvalho F, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-31
67. Kline T, Felise H, Barry K, et al. Substituted 2-imino-5- arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J Med Chem 2008;51:7065-74
68. Veenendaal A, Sundin C, Blocker A. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 2009;191:563-70
69. Larzábal M, Mercado E, Vilte D, et al. Designed coiled-coil peptides inhibit the type three secretion system of enteropathogenic Escherichia coli. PLoS ONE 2010;5:e9046
70. Larzábal M, Zotta E, Ibarra C, et al. Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorrhagic Escherichia coli O157:H7 and Citrobacter rodentium. Int J Med Microbiol IJMM 2013;303:9-15
71. Goure J, Broz P, Attree O, et al. Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis 2005;192:218-25
72. Heath D, Anderson G, Mauro J, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998;16:1131-7
73. Sawa T, Yahr T, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5:392-8
74. Shime N, Sawa T, Fujimoto J, et al. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol Baltim Md 1950;167:5880-6
75. François B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-6
76. Clinical Trials. Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. US National Institutes of Health, Bethesda, MD. Available from: http://clinicaltrials.gov/ct2/show/NCT01695343 [Last accessed 28 August 2013]
77. Surnamexu G, Surnameduggineni G, Surnameespitia G, et al. A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem Biophys Res Commun 2013;435:646-50
78. Kenny B, DeVinney R, Stein M, et al. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 1997;91:511-20
79. Donnenberg M, Tzipori S, McKee M, et al. The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. J Clin Invest 1993;92:1418-24
80. Harmon D, Davis A, Castillo C, Mecsas J. Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis. Antimicrob Agents Chemother 2010;54:3241-54
81. Bliska J, Copass M, Falkow S. The Yersinia pseudotuberculosis adhesin YadA mediates intimate bacterial attachment to and entry into HEp-2 cells. Infect Immun 1993;61:3914-21
82. Hudson D, Layton A, Field T, et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother 2007;51:2631-5
83. Negrea A, Bjur E, Ygberg S, et al. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2007;51:2867-76
84. Muschiol S, Normark S, Henriques-Normark B, Subtil A. Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells. BMC Microbiol 2009;9:75
85. Slepenkin A, Enquist P-A, Hägglund U, et al. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun 2007;75:3478-89
86. Tree J, Wang D, McInally C, et al. Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun 2009;77:4209-20
87. Nordfelth R, Kauppi A, Norberg H, et al. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 2005;73:3104-14
88. Abe H, Miyahara A, Oshima T, et al. Global regulation by horizontally transferred regulators establishes the pathogenicity of Escherichia coli. DNA Res Int J Rapid Publ Rep Genes Genomes 2008;15:25-38
89. Layton A, Hudson D, Thompson A, et al. Salicylidene acylhydrazide- mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. FEMS Microbiol Lett 2010;302:114-22
90. Gabrielsen M, Beckham KS, Feher VA, et al. Structural characterisation of Tpx from Yersinia pseudotuberculosis reveals insights into the binding of salicylidene acylhydrazide compounds. PLoS One 2012;7:e32217
91. Wang D, Zetterström CE, Gabrielsen M, et al. Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem 2011;286:29922-31
92. Martinez-Argudo I, Veenendaal A, Liu X, et al. Isolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motility. PloS One 2013;8:e52179
93. Wolf K, Betts H, Chellas-Géry B, et al. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 2006;61:1543-55
94. Slepenkin A, Chu H, Elofsson M, et al. Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide. J Infect Dis 2011;204:1313-20
95. Engström P, Nguyen BD, Normark J, et al. Mutations in hemG mediate resistance to Salicylidene acylhydrazides: a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity. J Bacteriol 2013;195:4221-30
96. Ochoa T, Clearly T. Lactoferrin disruption of bacterial type III secretion systems. Biometals Int J Role Met Ions Biol Biochem Med 2004;17:257-60
97. Mahmood F, Hakimiyan A, Jayaraman V, et al. A novel human antimicrobial factor targets Pseudomonas aeruginosa through its type III secretion system. J Med Microbiol 2013;62:531-9
98. Cantón R, Lumb J. Emerging resistance in Gram-negative pathogens and implications for clinical practice. Future Microbiol 2011;6:19-22
99. Bergeron J, Worrall L, Sgourakis N, et al. A refined model of the prototypical Salmonella SPI-1 T3SS basal body reveals the molecular basis for its assembly. PLoS Pathog 2013;9:e1003307
100. Marlovits T, Kubori T, Sukhan A, et al. Structural insights into the assembly of the type III secretion needle complex. Science 2004;306:1040-2
101. Schraidt O, Marlovits T. Three-dimensional model of Salmonella's needle complex at subnanometer resolution. Science 2011;331:1192-5
102. Dewoody R, Merritt P, Marketon M. Regulation of the Yersinia type III secretion system: traffic control. Front Cell Infect Microbiol 2013;3:4
103. Berger C, Crepin V, Baruch K, et al. EspZ of enteropathogenic and enterohemorrhagic Escherichia coli regulates type III secretion system protein translocation. mBio 2012;3:e00317-12
104. Huang Z, Sutton S, Wallenfang A, et al. Structural insights into host GTPase isoform selection by a family of bacterial GEF mimics. Nat Struct Mol Biol 2009;16:853-60
105. Heine S, Diaz-McNair J, Martinez-Becerra F, et al. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine 2013;31:2919-29
106. Potter A, Klashinsky S, Li Y, et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004;22:362-9
107. Worrall L, Bergeron J, Strynadka N. Chapter 14 - Type 3 secretion systems. In: Donnenberg M, editor. Escherichia coli: Pathotypes and principles of pathogenesis. 2nd revised edition. Academic Press, Salt Lake City, Utah. Elsevier Science & Technology Books 2013. p. 417-50
108. Yang J, Hocking DM, Cheng C, et al. Disarming bacterial virulence through chemical inhibition of the DNA-binding domain of an AraC-like transcriptional activator. J Biol Chem 2013; doi:10.1074/jbc.M113.503912